LB Pharmaceuticals raises $285M in first major biotech IPO since February

Core Insights - LB Pharmaceuticals raised $285 million in its initial public offering (IPO), marking the first significant stock offering for a young biotechnology company in over six months [1][3] - The company is developing LB-102, a drug for schizophrenia, which has shown promising results in mid-stage testing [2][4] Company Overview - LB Pharmaceuticals priced 19 million shares at $15 each, exceeding its initial projections [2] - The IPO is the largest of the year so far and breaks a prolonged period without large biotech IPOs, with the last one over $25 million occurring in February [3] Product Development - The proceeds from the IPO will be used to advance LB-102, which is a derivative of amisulpride, an existing antipsychotic [4] - Phase 2 data indicated that patients with acute schizophrenia treated with LB-102 showed improvement compared to those receiving a placebo [4] - The company plans to initiate a Phase 3 trial for schizophrenia and a mid-stage study for bipolar depression in Q1 2026 [4] Financial Background - Prior to the IPO, LB Pharmaceuticals raised over $120 million in private financing, with a significant portion from a $75 million Series C round [5] - The company had less than $15 million in cash and cash equivalents at the end of June [5] Industry Context - There has been a notable increase in acquisitions of neuropsychiatric medicines by large pharmaceutical companies, including Bristol Myers Squibb's $14 billion acquisition of Karuna Therapeutics and AbbVie's $9 billion purchase of Cerevel Therapeutics [6]